Skip to main content
Premium Trial:

Request an Annual Quote

Gates Foundation Provides Grant to IDRI for TB Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Seattle-based Infectious Disease Research Institute announced today it has received a multi-million dollar grant from the Bill and Melinda Gates Foundation to use "chemical genomics" medium- and high-throughput screening approaches to identify candidate targets against tuberculosis.

IDRI will identify and evaluate promising new drug-like compounds, which are active against Mycobacterium tuberculosis, with the goal of identifying new leads and new drug targets for further development. Ultimately the findings could lead to new therapies against the disease that kills about 2 million people each year.

The grant is part of the Foundation's TB Drug Accelerator program. Financial and other terms of the grant were not disclosed.

The Lilly TB Drug Discovery Initiative, which IDRI is part of, will provide the institute access to a library of about 800,000 compounds belonging to Eli Lilly. IDRI will leverage its expertise in molecular and microbial biology to identify novel targets for future screening, it said.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.